|
| Application | Components | Drug | References |
|
| Phase I trial for maximum tolerated dose and safety profile in intraperitoneal infusion in ovarian, breast, colon, stomach, and bladder cancer | Hyaluronic acid (HA) 10–12 KDa | Paclitaxel | [177] |
|
| In vivo cytotoxicity in peritoneal colorectal cancer | Hyaluronic acid ~200 KDa | Irrinotecan | [182] |
|
| HA-encapsulated drug delivery for metastatic breast, prostate, and colon cancer | Hyaluronic acid ~750 KDa | 5-FU, Doxorubicin | [185, 186] |
|
| Localized delivery in bone disease in cancer | Hyaluronic acid | Bisphosphonate | [187] |
|
| Nanoparticle delivery in colon cancer | Chitosan-hyaluronic acid | 5-FU | [190, 191] |
|
| Peritumoral delivery of nanovectors in head/neck squamas cell cancer (HNSCC) | Lipid-hyaluronic acid (1.2–5 MDa) | Mitomycin C | [192] |
| Hyaluronic acid | Cisplatin | [183] |
|
| Targeting with anti-CD44 antibodies in cancers including myeloid leukemia and HNSCC | Anti-CD44 antibody (Ab), humanized anti-CD44v6 monoclonal antibody (HAMA) labelled with technetium-99m | Anti-CD44Ab, Anti-CD44v6Ab | [231, 242–247] |
|
| Targeting in vitro breast cancer cells and xenograft lung tumor by interrupting HA-CD44 interaction | Small HA-oligosaccharides | 6–18 saccharide units (oHAs) | [11, 13, 41, 248, 249] |
|
| Targeting enzymatic degradation of HA in EMT-6 breast cancer cells, bladder cancer cells | bovine testicular, bacterial hyaluronidases,
HYAL1-1 | | [250, 251]
[252] |
|
| Targeting leukemia cell by nonviral vectors in leukemia K562 cells | Transferrin-PEG-test luciferase plasmid-nanoparticle | test luciferase plasmid | [253, 254] |
|
| In vivo targeting CD44v6 by tissue specific deletion of CD44 variant in intestine/colon tumor in Apc Min/+ mice | pSico-CD44v6shRNA plus pFabpl-Cre | CD44v6shRNA | [18, 43, 44, 255] |
|
